RECURSION PHARMACEUTICALS, INC. 8-K

What Happened

• Recursion Pharmaceuticals, Inc. filed an 8-K (Item 5.07) reporting the results of its 2026 annual meeting of stockholders held on June 17, 2026. Stockholders elected two Class II directors to serve until the 2029 annual meeting, approved the advisory executive compensation (say-on-pay) vote, and ratified PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for 2026.

Key Details

• Director elections (Class II, term to 2029):
  • Najat Khan, Ph.D.: For 210,437,751; Withheld 27,907,256; Broker non-votes 126,675,762.
  • Franziska Michor, Ph.D.: For 208,124,737; Withheld 30,220,270; Broker non-votes 126,675,762.
• Advisory vote on executive compensation (say-on-pay):
  • For 206,171,008; Against 30,893,147; Abstain 1,280,852; Broker non-votes 126,675,762.
• Appointment of auditor ratified:
  • PricewaterhouseCoopers LLP ratified as auditor for year ending Dec 31, 2026 — For 361,743,500; Against 2,148,771; Abstain 1,128,498.
• The company’s definitive proxy statement for the meeting was filed April 30, 2026.

Why It Matters

• These governance votes provide clarity and continuity: two directors were elected to the board through 2029, shareholders gave advisory approval to executive compensation, and PwC is confirmed as auditor for 2026. For investors, confirmed board composition, a passed say‑on‑pay vote, and a ratified independent auditor reduce near‑term governance uncertainty and signal shareholder support for management’s proposals.